![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS
BIOMIRA REPORTS LUNG CANCER DRUG STUDY RESULTS
April 28, 2006
Biomira has reported results from a clinical trial of its non-small cell lung cancer drug, Stimuvax.
The final survival results from an analysis of the Phase IIb data confirmed a median survival in patients with Stage IIIB cancer of 30.6 months with Stimuvax, while patients in the same stage who were in a control test group had a median survival of 13.3 months.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct